Prihlásiť sa Zaregistrujte sa zadarmo

Beta spoločnosti Acelrx Pharmaceuticals Inc

Aká je hodnota metriky Beta spoločnosti Acelrx Pharmaceuticals Inc?

Hodnota metriky Beta spoločnosti Acelrx Pharmaceuticals Inc je 0.85

Aká je definícia metriky Beta?



BETA koeficient vyjadruje či je akcia volatilnejšia ako celkový trh. Beta nižšie ako 1 značí, že akcia je menej volatilná ako trh a beta vyššie ako 1 značí, že akcia je volatilnejšia. Volatilita sa miera pomocou kolísavosti ceny akcie.

Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.

Beta spoločností v sektore Health Care sektor na NASDAQ v porovnaní so spoločnosťou Acelrx Pharmaceuticals Inc

Čomu sa venuje spoločnosť Acelrx Pharmaceuticals Inc?

acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v

Firmy s metrikou beta podobnou spoločnosti Acelrx Pharmaceuticals Inc